138 related articles for article (PubMed ID: 19020294)
21. Spatiotemporal patterns of putaminal dopamine processing in Parkinson's disease: A multi-tracer positron emission tomography study.
Fu JF; Wegener T; Klyuzhin IS; Mannheim JG; McKeown MJ; Stoessl AJ; Sossi V
Neuroimage Clin; 2022; 36():103246. PubMed ID: 36451352
[TBL] [Abstract][Full Text] [Related]
22. Quantitative study of
Jung Lung H; Weng YH; Wen MC; Hsiao IT; Lin KJ
Sci Rep; 2018 Oct; 8(1):16027. PubMed ID: 30375444
[TBL] [Abstract][Full Text] [Related]
23. Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson's disease.
Yoo HS; Chung SJ; Chung SJ; Moon H; Oh JS; Kim JS; Hong JY; Ye BS; Sohn YH; Lee PH
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):423-431. PubMed ID: 29075830
[TBL] [Abstract][Full Text] [Related]
24. Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.
Roussakis AA; Politis M; Towey D; Piccini P
Neurology; 2016 Mar; 86(12):1152-8. PubMed ID: 26920358
[TBL] [Abstract][Full Text] [Related]
25. Putaminal Dopamine Turnover in de novo Parkinson's Disease Predicts Later Neuropsychiatric Fluctuations but Not Other Major Health Outcomes.
Löhle M; Hermann W; Hausbrand D; Wolz M; Mende J; Beuthien-Baumann B; Oehme L; van den Hoff J; Kotzerke J; Reichmann H; Hermann A; Storch A
J Parkinsons Dis; 2019; 9(4):693-704. PubMed ID: 31381528
[TBL] [Abstract][Full Text] [Related]
26. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.
De La Fuente-Fernández R; Furtado S; Guttman M; Furukawa Y; Lee CS; Calne DB; Ruth TJ; Stoessl AJ
Synapse; 2003 Jul; 49(1):20-8. PubMed ID: 12710012
[TBL] [Abstract][Full Text] [Related]
27. [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor.
Breit S; Reimold M; Reischl G; Klockgether T; Wüllner U
J Neural Transm (Vienna); 2006 Feb; 113(2):187-93. PubMed ID: 15959851
[TBL] [Abstract][Full Text] [Related]
28. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.
Koeppe RA; Gilman S; Junck L; Wernette K; Frey KA
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S67-76. PubMed ID: 18632004
[TBL] [Abstract][Full Text] [Related]
29. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
[TBL] [Abstract][Full Text] [Related]
30. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
Boileau I; Rusjan P; Houle S; Wilkins D; Tong J; Selby P; Guttman M; Saint-Cyr JA; Wilson AA; Kish SJ
J Neurosci; 2008 Sep; 28(39):9850-6. PubMed ID: 18815269
[TBL] [Abstract][Full Text] [Related]
31. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
32. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
[TBL] [Abstract][Full Text] [Related]
33. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease.
Martin WR; Wieler M; Stoessl AJ; Schulzer M
Ann Neurol; 2008 Mar; 63(3):388-94. PubMed ID: 18240153
[TBL] [Abstract][Full Text] [Related]
34. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
35. Dopaminergic Nigrostriatal Connectivity in Early Parkinson Disease: In Vivo Neuroimaging Study of
Sanchez-Catasus CA; Bohnen NI; Yeh FC; D'Cruz N; Kanel P; Müller MLTM
J Nucl Med; 2021 Apr; 62(4):545-552. PubMed ID: 32859707
[TBL] [Abstract][Full Text] [Related]
36. Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis.
Lee CS; Schulzer M; de la Fuente-Fernández R; Mak E; Kuramoto L; Sossi V; Ruth TJ; Calne DB; Stoessl AJ
Arch Neurol; 2004 Dec; 61(12):1920-5. PubMed ID: 15596613
[TBL] [Abstract][Full Text] [Related]
37. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease.
de la Fuente-Fernández R; Schulzer M; Kuramoto L; Cragg J; Ramachandiran N; Au WL; Mak E; McKenzie J; McCormick S; Sossi V; Ruth TJ; Lee CS; Calne DB; Stoessl AJ
Ann Neurol; 2011 May; 69(5):803-10. PubMed ID: 21246604
[TBL] [Abstract][Full Text] [Related]
38. Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
Fu JF; Matarazzo M; McKenzie J; Neilson N; Vafai N; Dinelle K; Felicio AC; McKeown MJ; Stoessl AJ; Sossi V
Mov Disord; 2021 Feb; 36(2):389-397. PubMed ID: 33090574
[TBL] [Abstract][Full Text] [Related]
39. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study.
Pavese N; Evans AH; Tai YF; Hotton G; Brooks DJ; Lees AJ; Piccini P
Neurology; 2006 Nov; 67(9):1612-7. PubMed ID: 17101892
[TBL] [Abstract][Full Text] [Related]
40. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study.
Sossi V; Dinelle K; Topping GJ; Holden JE; Doudet D; Schulzer M; Ruth TJ; Stoessl AJ; de la Fuente-Fernandez R
J Neurochem; 2009 Apr; 109(1):85-92. PubMed ID: 19183257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
